There are 3161 resources available
191P - Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors
Presenter: Francesco Facchinetti
Session: Poster session 08
192P - Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers
Presenter: Daniel Palmer
Session: Poster session 08
193P - Translational, PK, PD, and immunophenotyping analyses of tuvusertib + niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301)
Presenter: Anthony Tolcher
Session: Poster session 08
194P - CD8-to-CD20 lymphocyte ratio is a predictive biomarker for lenvatinib and pembrolizumab efficacy and progression-free survival in advanced endometrial cancer: Updated data
Presenter: Liubov Tashireva
Session: Poster session 08
195P - Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer
Presenter: Eva Colas
Session: Poster session 08
196P - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Presenter: Richard Schlenk
Session: Poster session 08
197P - PRIME-ROSE: Merging clinical outcome data from DRUP-like clinical trials
Presenter: Tina Kringelbach
Session: Poster session 08
198P - Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 08
199P - Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival
Presenter: qingsheng xie
Session: Poster session 08
200P - Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
Presenter: Tilmann Bochtler
Session: Poster session 08